Please sign in to follow a disease.
Breathing in a special gas reveals hidden lung damage in COVID survivors
NCT ID NCT04659707
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at lung function in 42 people recovering from COVID-19. Participants inhaled a special form of xenon gas that shows up on MRI scans, allowing researchers to see how well different parts of the lungs were working. The goal was to understand how mild, moderate, and severe COVID-19 affect lung structure and function over six months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Hyperpolarized xenon gas (inhaled for MRI imaging)
- What this could lead to
- If successful, this could help doctors better understand how COVID-19 affects the lungs over time and guide recovery monitoring.
- What could go wrong
- This is a small, early-phase study with only 42 participants, so results may not apply to everyone. It is designed to observe, not treat, the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
42 people
The number who actually took part.
- Started
-
Feb 2021
- Finished
-
May 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Oxygenation saturation of ≥88% at rest by study staff within 48 hours prior to study entry. * The participant has a previous diagnosis of COVID-19 confirmed by COVID-19 PCR or antibody testing and is being seen for outpatient follow-up. * Subject is at least 10 days post-symptom-onset and do not have a fever (\<99.5°). * Ability to read and understand English or Spanish Exclusion Criteria: * Subject is less than 18 years old * MRI is contraindicated based on responses to MRI screening questionnaire * Subject is pregnant or lactating * Subject does not fit into 129Xe vest coil used for MRI * Subject cannot hold his/her breath for 15-16 seconds * Subject deemed unlikely to be able to comply with instructions during imaging * Oxygen saturation \<88% on room air or with supplemental oxygen * Cognitive deficits that preclude ability to provide consent * Institutionalization
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID19 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Home antibody tests put to the test: can you read your own COVID-19 result?
- COVID-19's hidden toll: muscle wasting in the ICU
- Can a mild case of COVID-19 harm your kidneys? urine tests may hold the answer
- Could a common acne pill weaken the nose's defense against COVID-19?
- Could cystic fibrosis offer hidden protection against COVID-19?
- Could a different way of pedaling rebuild muscles after severe COVID-19?